ASPET Annual Meeting at EB 2014 News
Follow ASPET's tweets and Facebook posts about the meeting. On Twitter, our program-related posts will have the hashtag #xBio. We encourage you to use #xBio and #ASPET on Twitter in your discussions about the ASPET Annual Meeting at EB 2014.
Official Blogger for ASPET Annual Meeting at EB 2013
Katiesci will be ASPET’s Official Meeting Blogger at the ASPET Annual Meeting at EB 2013! Follow the action in Boston with Katiesci’s blog, Sickness is Fascinating (http://sicknessisfascinating.blogspot.com/).
Meeting updates will also be posted to Twitter by @ASPET. On Twitter, our program-related posts will have the hashtag #EB2013. We encourage you to use #EB2013 and #ASPET13 on Twitter in your discussions about the ASPET Annual Meeting at EB 2013.
ASPET Announces Award Winners for 2013
Julius Axelrod Award
John Jacob Abel Award
Pharmacia-ASPET Award for Experimental Therapeutics
Robert R. Ruffolo Career Achievement Award in Pharmacology
Torald Sollmann Award in Pharmacology
Benedict R. Lucchesi Distinguished Lectureship in Cardiac Pharmacology
ASPET Division for Drug Metabolism Early Career Achievement Award
For additional information on the 2013 ASPET Award winners, contact Jim Bernstein at 301-634-7062.
Lee E. Limbird, Ph.D.
Lee Limbird, Professor of Biochemistry and Dean of the School of
Natural Sciences at Fisk University has been named recipient of the 2013
Julius Axelrod Award in Pharmacology by the American Society for
Pharmacology and Experimental Therapeutics (ASPET). Dr. Limbird is
recognized for her major contributions to research and her outstanding
leadership and mentorship to several generations of graduate students.
The Julius Axelrod Award, named after the 1970 Nobel Prize winner in
Physiology or Medicine, is given to recognize outstanding scientific
contributions in research and mentoring in pharmacology. The Award was
established to honor the memory of the eminent American pharmacologist
who shaped the fields of neuroscience, drug metabolism, and
Dr. Limbird obtained her Bachelor’s
degree in Chemistry from the College of Wooster in Ohio and earned her
Ph.D. from the University of North Carolina. After post-doctoral
research at Duke University, she joined the Department of Pharmacology
at Vanderbilt University, where she would chair the department and later
serve as Vanderbilt University Medical Center’s first Associate Vice
Chancellor for Research. She represented Vanderbilt on numerous state
academic partnerships. In 2005, she joined Meharry Medical College as
Vice President for Research and Chair of the multidisciplinary
Department of Biomedical Sciences. Dr. Limbird would move to Fisk
University in 2008.
Since her post-doctoral fellowship at
Duke under Nobel Laureate Robert Lefkowitz, Dr.Limbird’s research career
has focused on G-protein coupled receptors. Her research on alpha-2
adrenergic receptors is considered pioneering and showed how those
specific receptors relate to regulation of blood pressure, sedation,
pain suppression, and opioid drug action. She has also devised
strategies for selective manipulation of these receptors, opening up
opportunities for therapeutic development.
In addition to her many significant
research discoveries, Dr. Limbird is credited with many for bringing
Vanderbilt’s Department of Pharmacology to its leading position. Her
devotion to Vanderbilt’s academic excellence, mentoring and nurturing of
students, postdocs, and young faculty are legendary and extend to
offering personal support for many student related activities including
travel to meetings. While at Vanderbilt, she developed a partnership
with Meharry’s Department of Pharmacology to catalyze interactions
between the two departments.
Dr. Limbird has been a recipient of many
awards including ASPET’s John Jacob Abel Award for young investigators
and the Goodman and Gilman Award for Receptor Pharmacology. She has
served on numerous NIH review committees and has been active in ASPET
serving as Councilor, Secretary/Treasurer, and in other leadership
capacities. She has received many teaching awards given by the graduate
students themselves, and many of her own doctoral and post-doctoral
students are among the most successful in academia and industry.
Dr. Limbird will be presented the
ASPET-Julius Axelrod Award in Pharmacology on Saturday, April 20 at the
ASPET Business Meeting/Awards Ceremony of the Annual Meeting of the
American Society for Pharmacology and Experimental
Therapeutics/Experimental Biology (EB) 2013 Meeting in Boston, MA. The
ASPET Business Meeting and Awards Ceremony will take place at the Boston
Convention Center, Room 107AB from 6:00 – 7:30 p.m. immediately
followed by the Opening Reception. Dr. Limbird will give the 2014 Julius
Axelrod Lecture. The 2013 Julius Axelrod Award Lecture will be given by
last year’s recipient, Gavril W. Pasternak, Ph.D., of Memorial Sloan
Kettering Cancer Center. Dr. Pasternak will deliver a lecture titled,
“No pain, big gain: Truncated mu opioid receptor splice variants as drug
targets,” on Sunday, April 21 from 2:00 – 2:50 p.m. in Room 107AB in
the Boston Convention Center.
Arthur Christopoulos, Ph.D.
Christopoulos, Ph.D., Professor of Pharmacology at Monash University
and Principal Research Fellow of the National Health and Medical
Research Council of Australia, is the recipient of the 2013 John J. Abel
Award, sponsored by Pfizer. Dr. Christopoulos receives the John J. Abel
Award as an outstanding young investigator in recognition of his
fundamental contributions to the field of analytical pharmacology and
the study of G protein-coupled receptors, notably in his work on
allosteric modulation and biased signaling of GPCRs.
Dr. Christopoulos is one of the world’s
leading receptor pharmacologists. His key contributions to the field
have been the dissemination of the concept of GPCR allosterism and the
development of assays and analytical procedures that facilitate the
detection, validation, and quantification of allosteric drug effects and
ligand-based signaling. This work has had a major impact on modern GPCR
focused drug discovery.
Dr. Christopoulos received his Ph.D. from
the Victorian College of Pharmacy at Monash University in Australia.
Following his post-doctoral training at the University of Minnesota, he
returned to Australia and established his own laboratory with a view to
develop analytical pharmacology techniques to address many of the
preclinical challenges of modern drug discovery. More recently, his work
has turned to understanding the structural basis underlying allosteric
modulator effects at GPCRs as well as overcoming translational
bottlenecks in progressing modulator-focused drug discovery programs.
He is the highest-ranked Australian based
scientist in the disciplines of pharmacology and toxicology.
Additionally, Dr. Christopoulos also serves on the editorial board of
eight international journals, including Molecular Pharmacology and the Journal of Pharmacology and Experimental Therapeutics.
Dr. Christopoulos will be presented the
2013 John J. Abel Award on Saturday, April 20 at the Business
Meeting/Awards Ceremony of the Annual Meeting of the American Society
for Pharmacology and Experimental Therapeutics/Experimental Biology (EB)
2013 Meeting in Boston, MA. The ASPET Business Meeting/Awards Ceremony
will take place at the Boston Convention Center, room 107AB from 6:00 –
7:30 p.m. immediately followed by the Opening Reception. Dr.
Christopoulos’ John J. Abel Award Lecture is titled, “Reciprocal
relationships: The yin and yang of GPCR allostery” and will be delivered
on Monday, April 22 from 8:30 – 9:20 a.m. in Room 107C at the Boston
Richard R. Neubig, M.D., Ph.D.
Richard R. Neubig, Professor in the Department of Pharmacology,
co-director of the Center for Chemical Genomics, and Director of the
Center for the Discovery of New Medicines at the University of Michigan,
is the recipient of the 2013 Pharmacia-ASPET Award for Experimental
Therapeutics. The Pharmacia-ASPET Award for Experimental Therapeutics is
given annually to recognize and stimulate outstanding research in
pharmacology and experimental therapeutics—basic laboratory or clinical
research that has had, or potentially will have, a major impact on the
pharmacological treatment of disease. This award is funded by an
endowment from Pharmacia (now Pfizer) and by ASPET.
Dr. Neubig earned his dual degrees from
Harvard and undertook an internal medicine residency at the University
of Michigan. After that he was appointed as Assistant Professor in the
Department of Pharmacology. He quickly established himself as an
international authority on the biochemistry and pharmacology of the
Together with colleagues, he helped
establish the Center for Chemical Genomics (CCG) where investigators
across the university have isolated several novel compounds that could
lead to the development of novel therapeutics. The success of the CCG
was recognized by the University when it named him the Director of the
Center of Discovery of New Medicines.
Dr. Neubig is President-elect of ASPET
and has been active in the International Union of Pharmacology. He is
co-founder of the Great Lakes GPCR Retreat, an annual meeting that has
gained international stature and is now considered one of the field’s
most informative and intense conferences focusing on GPCR signaling. He
has also made significant contributions to education and mentorship. He
has contributed to graduate and medical school curriculum and serves as
course director or co-director of several courses. He has served as
thesis advisor for over 60 graduate students.
Dr. Neubig will be presented the
Pharmacia-ASPET Award on Saturday, April 20 at the Business Meeting
Awards Ceremony of the Annual Meeting of the American Society for
Pharmacology and Experimental Therapeutics/Experimental Biology (EB)
2013 Meeting in Boston, MA. The ASPET Business Meeting/Awards Ceremony
will take place at the Boston Convention Center, Room 107AB from 6:00 –
7:30 p.m. immediately followed by the Opening Reception.
Pancras C. Wong, Ph.D.
Pancras C. Wong, Senior Research Fellow at Bristol-Myers Squibb
Company, is the recipient of the 2013 Robert R. Ruffolo Career
Achievement Award in Pharmacology. The award was established in
recognition of the contributions made to drug discovery and development
by Dr. Ruffolo, former President of Research and Development at Wyeth
Pharmaceuticals, and is given to recognize the scientific achievements
of scientists who are at the height of their careers and who have made
significant contributions to any area of pharmacology. Dr. Wong has
dedicated 30 years to drug discovery research and has co-discovered two
breakthrough medicines in two different therapeutic areas.
After receiving his Ph.D. at the
University of Minnesota, Dr. Wong began his pharmaceutical career as a
Senior Research Pharmacologist in Hoechst-Roussell Pharmaceuticals. He
joined the DuPont Company in 1983 to conduct research in hypertension
and heart failure.
While at DuPont, Dr. Wong played an
integral role in the discovery of receptor subtypes for angiotensin II,
AT1 and AT2, the characterization of the biological functions of these
receptor subtypes, and the identification of losartan as a selective AT1
receptor antagonist. Losartan is now marketed under the trade name
At Bristol-Myers Squibb, Dr. Wong
conducts research focused on developing new antithrombotic drugs. The
research goal was to discover novel oral anticoagulants with improved
safety, efficacy, and ease of use compared with warfarin, the standard
of care. Dr. Wong’s work contributed to the development of apixaban to
reduce the risk of stroke and systemic embolism in patients with
nonvalvular atrial fibrillation. Recently, apixaban has been approved
for this indication in the U.S., Europe, Japan, and Canada.
Dr. Wong has published over 150 papers
and book chapters. He was selected as a recipient of the American
Chemical Society Award for Team Innovation in 1997 and the Ondetti &
Cushman Award for Scientific Innovation from Bristol-Myers Squibb in
2011. He has been a longstanding member of ASPET and is an elected
Fellow of the American Heart Association.
Dr. Wong will be presented the Robert R.
Ruffolo Career Achievement Award in Pharmacology on Saturday, April 20
at the Business Meeting Awards Ceremony of the Annual Meeting of the
American Society for Pharmacology and Experimental
Therapeutics/Experimental Biology (EB) 2013 Meeting in Boston, MA. The
ASPET Business Meeting/Awards Ceremony will take place at the Boston
Convention Center, Room 107AB from 6:00 – 7:30 p.m. immediately followed
by the Opening Reception.
William L. Dewey, Ph.D.
L. Dewey, Ph.D., Professor and Chair of the Department of Pharmacology
and Toxicology at the Virginia Commonwealth University, is the recipient
of the 2013 Torald Sollmann Award. The Award was established to
commemorate the pioneering work in America of Dr. Torald Sollmann in the
fields of pharmacological investigation and education. Dr. Dewey was
selected for this award because of his outstanding and productive
research career; his significant contributions to medicine utilizing
education, research, and service; and his unparalleled service to ASPET
and the discipline it represents.
Dr. Dewey earned his Ph.D. from the
University of Connecticut. Upon completion of his postdoctoral work at
the University of North Carolina, he was offered a position there as
Assistant Professor of Pharmacology. In 1972, he was recruited to VCU,
where he has served numerous positions including Vice Chair for
Research, Dean of the School of Basic Health Sciences, Associate
Provost, and Vice President for Research and Graduate Studies. His
distinguished research has pioneered approaches to understand mechanisms
of substance abuse, including significant findings on the mechanism of
action of opioid agonists and antagonists and the cannabinoids. His
collaborative research helped discover that an increase in endogenous
opioids occurred in sudden infant death syndrome (SIDS) and led to the
development of therapeutics for the treatment of SIDS and other diseases
with centrally induced respiratory depression. In addition to his
opioid work, his research has contributed significantly to pharmacology
and our understanding of the mechanisms of tolerance to marihuana.
In addition to his excellent mentoring of
dozens of doctoral and postdoctoral trainees, Dr. Dewey’s contributions
to pharmacology education are nationally recognized. He is the founder,
President and Treasurer of The Friends of the National Institute on
Drug Abuse, a coalition of over 100 organizations which advocates for
research, treatment, and prevention of substance abuse. He served as
President of ASPET and tirelessly contributed to numerous other
leadership roles within the society for many years, including chairing
the Centennial Celebration Committee. He is a past President of the
Federation of American Societies for Experimental Biology (FASEB) and
twice was elected to lead the College on Problems of Drug Dependence. As
appointed Chairman of the Virginia Biotechnology Research Act Study
Committee, he played a major role in the passage of the act and served
as the first Vice President of the Virginia Biotechnology Research Park.
Dr. Dewey will be presented the Torald
Sollmann Award on Saturday, April 20 at the Business Meeting Awards
Ceremony of the Annual Meeting of the American Society for Pharmacology
and Experimental Therapeutics/Experimental Biology (EB) 2013 Meeting in
Boston, MA. The ASPET Business Meeting/Awards Ceremony will take place
at the Boston Convention Center, Room 107AB from 6:00 – 7:30 p.m.
immediately followed by the Opening Reception.
Andre Terzic, M.D., Ph.D.
Terzic, M.D., Ph.D., Professor of Medicine and Pharmacology, Marriott
Family Endowed Professor in Cardiovascular Diseases, and Director of the
Center for Regenerative Medicine at the Mayo Clinic, is recipient of
the 2013 Benedict Lucchesi Award in Cardiac Pharmacology. The biennial
award was established by the American Society for Pharmacology and
Experimental Therapeutics to honor Dr. Lucchesi’s lifelong scientific
contributions to our better understanding and appreciation of
pharmacological treatment and prevention of cardiovascular disease and
for his mentoring of many cardiovascular pharmacologists. The Awards
Committee selected Dr. Terzic in recognition of his scientific
leadership as an international leader in cardiac pharmacology.
A native of Paris (France), Dr. Terzic
received medical and graduate education at the Universities of Belgrade,
Paris, and Illinois (Chicago), followed by fellowship training at the
French National Institutes of Health, Thomas Jefferson University, and
the Mayo Clinic. Dr. Terzic would become the youngest faculty with dual
academic rank of Professor in Medicine and Pharmacology at Mayo Clinic,
and its inaugural director of Regenerative Medicine.
Dr. Terzic has made landmark
contributions in our understanding of cardioprotective and
cardioregenerative strategies. His early career contributions began with
pioneering studies into the mechanisms by which ATP-sensitive potassium
channels bring about cardioprotection. His laboratory leads the world
in discoveries of the principles by which these ion channels mediate
cardiac protection and how to therapeutically target them to prevent
cardiac injury. Dr. Terzic’s more recent efforts in regenerative science
have drawn international attention representing cutting-edge
translational research. He has led efforts in the development of next
generation cardiovascular regenerative therapies, including the
first-in-man clinical trial using organ-specified stem cells for heart
repair. His scientific success is matched by his outstanding mentorship
and dedication to the scientific and medical community.
Dr. Andre Terzic has had to cancel his presentation of the Benedict Lucchesi Lecture in Cardiac Pharmacology scheduled for Tuesday, April 23, from 4:30 – 5:30 p.m. in Room 107AB of the Boston Convention Center, Boston, MA. Instead, Dr. Lucchesi, himself, will give a lecture on his pioneering research entitled, “Reperfusion injury: Can it be prevented?” and Dr. Terzic will deliver the Benedict Lucchesi Lecture in Cardiac Pharmacology at the ASPET Annual Meeting at EB 2015 in Boston, MA.
Nina Isoherranen, Ph.D.
Nina Isoherranen, Associate Professor in the Department of
Pharmaceutics at the University of Washington, is the recipient of the
2013 Drug Metabolism Early Career Achievement Award. The Award was
established by ASPET’s Division for Drug Metabolism to recognize
excellent original research by early career investigators in the area of
drug metabolism and disposition.
Dr. Isoherranen received her Bachelor’s
and Master’s of Science degrees from the University of Helsinki. After
earning her Ph.D. in Pharmaceutical Sciences from the Hebrew University
in Jerusalem, Israel, she continued her training as a postdoctoral
fellow at the University of Washington, joining the Department of
Pharmaceutics as an Acting Assistant Professor and soon after as
Dr. Isoherranen’s work has centered on
characterizing the complex drug-drug interaction scenarios involving
inhibitory metabolites and multiple-P450 inhibitors; understanding of
the expression, activity, and physiological importance of CYP26 enzymes
in retinoic acid metabolism; and the role of drug metabolizing enzymes
during pregnancy and fetal development. She has established herself as a
leader and pioneer in the prediction of complex drug-drug interactions.
Dr. Isoherranen is committed to the
advancement of education and training of graduate students, professional
Pharm.D. students, and post-doctoral fellows, as well as supporting the
progress of the drug metabolism field. She has been honored with many
awards, among them the Kaye Innovation Award from the Hebrew University,
Young Investigator Award from the American Epilepsy Society, and the
Distinguished Ph.D. Student prize from the Hebrew University.
Dr. Isoherranen’s lecture, titled “The
biochemistry and clinical significance of CYP26 enzymes in regulating
retinoic acid homeostasis,” will be presented on Monday, April 22 from
2:00 – 2:50 p.m. in Room 108 of the Boston Convention Center.